<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900600</url>
  </required_header>
  <id_info>
    <org_study_id>HM13782</org_study_id>
    <secondary_id>20110521</secondary_id>
    <nct_id>NCT01900600</nct_id>
  </id_info>
  <brief_title>Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)</brief_title>
  <official_title>Substudy of the the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP; CACZ885M2301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a sub-study of the CANTOS trial (A randomized, double-blind,
      placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the
      prevention of recurrent cardiovascular events among stable post-myocardial infarction
      patients with elevated high sensitivity C-reaction protein (hsCRP) [CACZ885M2301]).

      The study proposes to perform serial Cardiopulmonary Exercise Tests (CPX) to prospectively
      measure changes in aerobic exercise capacity in patients with prior myocardial infarction
      (MI), elevated C reactive protein plasma levels, and symptomatic heart failure with reduced
      systolic function, who are enrolled in the main CANTOS trial and are randomly assigned to
      Canakinumab (3 different doses) or Placebo.

      The subjects enrolled in this substudy will undergo repeated CPX and echocardiograms over the
      first 12 months of the CANTOS trial. The subjects will received the experimental treatment as
      randomized in the main CANTOS trial and they will not receive any additional experimental
      treatment as part of the sub-study.

      This study is a an Investigator-initiated (Dr. Abbate) single-center (Virginia Commonwealth
      University) sub-study of the CANTOS trial, supported by Novartis pharmaceuticals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in the CANTOS trial (with prior acute myocardial infarction [&gt;30 days] and
      elevated C reactive protein levels [CRP&gt;2mg/l]) who also have reduced left ventricular
      ejection fraction (LVEF&lt;50%) and are symptomatic for heart failure (New York Heart
      Association symptoms class II-III) will be offered to take part in this sub-study at the
      Virginia Commonwealth University site.

      As part of the sub-study, patients will undergo a cardiopulmonary exercise test (CPX) at
      baseline prior to initiation of treatment, then repeated at 3 and 12 months, and a
      transthoracic echocardiogram at baseline and at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen consumption (VO2)</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in the interval change from baseline in peak VO2 at 3 months following a single dose of CANAKINUMAB 50 mg subcutaneous, 150 mg subcutaneous, or CANAKINUMAB 300 mg subcutaneous [all three groups combined] when compared with the interval change in placebo (placebo-corrected interval change).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak VO2 change</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the interval changes from baseline and 12 months in peak VO2 comparing CANAKINUMAB (all doses) with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory efficiency (VE/VCO2 slope) change</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the interval changes from baseline and 3 months in the VE/VCO2 slope comparing CANAKINUMAB (all doses) with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OUES</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the interval changes from baseline and 12 months in oxygen utilization efficiency slope (OUES) comparing CANAKINUMAB (all doses) with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF change</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the interval changes from baseline and 12 months in left ventricular ejection fraction (LVEF) comparing CANAKINUMAB (all doses) with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function change</measure>
    <time_frame>12 months</time_frame>
    <description>Difference in the interval changes from baseline and 12 months in E/E' (diastolic function) comparing CANAKINUMAB (all doses) with placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Prior Acute Myocardial Infarction</condition>
  <condition>Evidence of Systemic Inflammation (C Reactive Protein Plasma &gt;2 mg/l)</condition>
  <condition>Reduced Left Ventricle Ejection Fraction (&lt;50%)</condition>
  <condition>Symptoms of Heart Failure (NYHA Class II-III)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canakinumab 50 mg quarterly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Canakinumab 50 mg quarterly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canakinumab 150 mg quarterly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Canakinumab 150 mg quarterly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canakinumab 300 mg quarterly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Canakinumab 300 mg quarterly</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary exercise test</intervention_name>
    <description>All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Canakinumab 50 mg quarterly</arm_group_label>
    <arm_group_label>Canakinumab 150 mg quarterly</arm_group_label>
    <arm_group_label>Canakinumab 300 mg quarterly</arm_group_label>
    <other_name>Cardiopulmonary exercise test (CPX)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Canakinumab 50 mg quarterly</arm_group_label>
    <arm_group_label>Canakinumab 150 mg quarterly</arm_group_label>
    <arm_group_label>Canakinumab 300 mg quarterly</arm_group_label>
    <other_name>Echocardiogram or Echo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all criteria listed in the CANTOS trial (CACZ885M2301)

          -  left ventricular ejection fraction &lt;50%

          -  symptoms of heart failure (NYHA class II-III)

        Exclusion Criteria:

          -  all criteria listed in the CANTOS trial (CACZ885M2301)

          -  inability to complete a treadmill exercise test

          -  conditions preventing interpretation of the cardiopulmonary test (arrhythmias,
             ischemia, hypertension, pulmonary disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.thecantos.org/cantos-summary.html</url>
    <description>Main CANTOS website</description>
  </link>
  <reference>
    <citation>Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1Î² inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011 Oct;162(4):597-605. doi: 10.1016/j.ahj.2011.06.012. Epub 2011 Sep 14.</citation>
    <PMID>21982649</PMID>
  </reference>
  <reference>
    <citation>Abbate A, Van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs. 2012 Aug 1;26(4):217-33. doi: 10.2165/11631570-000000000-00000. Review.</citation>
    <PMID>22571369</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

